Supriya Lifescience Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Supriya Lifescience (NSE: SUPRIYA) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 580 — against a 52-week high of Rs 780 and 1-year return of -20% — the Q4 FY26 results will be a pivotal event for investors.

Analyst estimates for Q4 FY26 revenue stand at Rs 350-380 Cr, with PAT expectations of Rs 96-110 Cr and margin projections of EBITDA 38-41%. This article covers the Supriya Lifescience Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and investor FAQs.

Supriya Lifescience Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Why This Quarter Matters

Supriya Lifescience enters Q4 FY26 with expectations of 10-14% YoY revenue growth. Q4 determines full-year FY26 performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of -20%, this quarter’s results and FY27 guidance will be critical for determining stock trajectory.

Supriya Lifescience Q4 FY26 Earnings Estimates

Supriya Lifescience Q4 FY26 analyst estimates. Source: MOFSL, YES Securities, JM Financial.

Access premium SEBI-registered research on Univest.

Screen Supriya Lifescience fundamentals on Univest Screener.

5 Key Factors That Will Drive Supriya Lifescience Q4 FY26 Performance

Revenue Momentum

Analysts expect Rs 350-380 Cr in Q4 FY26 revenue versus Rs 318 Cr in Q3. Q4 is seasonally important for the Pharma/API sector and the ability to convert the pipeline into recognised revenue will be the first performance test.

Margin Trajectory

Q4 FY26 margin expectations are EBITDA 38-41% versus EBITDA 38.4% in Q3. Input cost trends, employee expenses, and pricing power will determine whether the company can sustain or improve on Q3 levels.

PAT Quality

Net profit is estimated at Rs 96-110 Cr. Investors will assess whether PAT is driven by operational improvement or non-recurring items. A clean recurring profit print is most positively received by institutional investors.

Management Guidance for FY27

The most consequential output will be FY27 guidance — revenue growth bands, margin targets, and capex plans. Credible FY27 guidance carries significant weight for re-rating potential in the current macro environment.

Dividend Declaration

Supriya Lifescience is expected to consider a final dividend of Rs 4-6 per share. The quantum signals management’s confidence in free cash flow generation and sets expectations for FY27 capital allocation.

5 Risks to Watch in Supriya Lifescience Q4 FY26

US Tariff and Macro Headwinds

The 26% US reciprocal tariff on Indian goods has created macro uncertainty. For Supriya Lifescience, indirect impacts include FII outflows and earnings estimate cuts if global demand slows.

Earnings Miss Risk

If Supriya Lifescience’s Q4 FY26 results miss estimates, the stock could correct sharply. Investors should monitor revenue versus Rs 350-380 Cr and PAT versus Rs 96-110 Cr as the two primary watchpoints.

FY27 Guidance Below Consensus

If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. Forward guidance carries more weight than the reported quarter currently.

FII Outflow Continuation

FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling creates headwinds for Supriya Lifescience regardless of fundamentals.

Sector Regulatory Risk

The Pharma/API sector faces evolving regulatory frameworks. Policy changes that increase compliance costs or alter competitive dynamics could affect Supriya Lifescience’s profitability.

Supriya Lifescience Share Price and Analyst Ratings

Supriya Lifescience share price snapshot and analyst ratings. Source: Brokerages, NSE data.

Supriya Lifescience is trading at Rs 580 as of early April 2026, against a 52-week high of Rs 780 and 52-week low of Rs 440. Market cap stands at Rs 3,700 Cr.

Download the Univest iOS App or Univest Android App to track Supriya Lifescience live and receive real-time Q4 result alerts.

Conclusion

Supriya Lifescience Q4 FY26 results on May 2026 (Expected) will be a key event for Pharma/API sector investors. Analysts project PAT of Rs 96-110 Cr and revenue of Rs 350-380 Cr. At Rs 580 with analyst targets from Rs 710 to Rs 750, FY27 guidance will be the most critical post-results catalyst.

For more Q4 FY26 previews, visit Univest Blogs.

Frequently Asked Questions

What is the Supriya Lifescience Q4 results 2026 date?

The Supriya Lifescience Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a final dividend recommendation.

What is the Supriya Lifescience Q4 FY26 PAT estimate?

Analysts estimate Supriya Lifescience Q4 FY26 PAT at Rs 96-110 Cr, based on revenue of Rs 350-380 Cr and margin of EBITDA 38-41%.

What is Supriya Lifescience’s share price ahead of Q4 results?

Supriya Lifescience is trading at Rs 580. The 52-week high is Rs 780 and low is Rs 440. The 1-year return is -20% and market cap is Rs 3,700 Cr.

Will Supriya Lifescience declare a dividend in Q4 FY26?

Supriya Lifescience is expected to consider a final dividend of Rs 4-6 per share at the Q4 FY26 board meeting on May 2026 (Expected).

Which analysts have a Buy rating on Supriya Lifescience?

MOFSL (Buy, Rs 750), YES Securities (Buy, Rs 730), JM Financial (Add, Rs 700), Emkay (Buy, Rs 710) have positive ratings heading into Q4 FY26.

What were Supriya Lifescience Q3 FY26 results?

Supriya Lifescience reported Q3 FY26 revenue of Rs 318 Cr and PAT of Rs 88 Cr, with margin at EBITDA 38.4%.

When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read both previews on Univest Blogs.

Is Supriya Lifescience a good investment ahead of Q4 results?

This depends on your risk appetite. Supriya Lifescience has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before investing.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only. All financial data and analyst estimates are sourced from publicly available information. Verify before investing. Consult a SEBI-registered advisor before making investment decisions.

Recent Article

TCS Share Price Target 2026 — Key Factors, Financial Performance & Analyst Forecast

Nestle India Share Price Target 2026 — Key Factors, Financial Performance & Analyst Forecast

State Bank of India Share Price Target 2026: Analyst Forecasts, Bull & Bear Case

Hindustan Unilever Share Price Target 2026 — Key Factors, Financial Performance & Analyst Forecast